Event-Driven Stocks

Blueprint Medicines Corp

BPMC

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 1 good● 5 warningdetails ↓

Financials

SEC XBRL · annual
 FY24FY23FY22FY21FY20FY19
Revenue$508.8M$249.4M$204.0M$180.1M$793.7M$66.5M
Operating income——————
Net income−$67.1M−$507.0M−$557.5M−$644.1M$313.9M−$347.7M
Total assets$1.18B$1.05B$1.35B$1.25B$1.72B$707.7M
Total liabilities$881.1M$918.6M$835.2M$281.5M$248.3M$243.3M
Equity$298.7M$130.6M$514.7M$970.7M$1.47B$464.4M
EPS (diluted)$-1.07$-8.37$-9.35$-11.01$5.59$-7.27
Shares out.61.2M60.0M59,20358.0M54.0M44.1M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2024
Operating margin
—
Net margin
−13.2%
Return on equity
−22.5%
Return on assets
−5.7%
Return on capital (ROCE)
—
Liabilities / assets
74.7%
Debt / equity
2.95×
Book value / share
$4.88
Revenue growth (YoY)
104.0%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2024
Accruals / assets
10.6%high accruals
Beneish M-Score
-0.77elevated
Piotroski F-Score
3/8weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
40
/ 100
Profitability 0Growth 100Catalyst 33Earnings quality 0Financial strength 67

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 5 warning● 1 good
  • Reported a net loss
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • High accruals — earnings-quality risk
  • Beneish M-Score elevated — earnings-manipulation screen flag
  • Revenue is growing year-over-year

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

FDA-approved drugs

openFDA · most recent
  • GAVRETODec 1, 2020
  • AYVAKITJan 9, 2020

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
Jul 15, 20251.7M1.0-54.7%
Jun 30, 20253.7M1.1+17.6%
Jun 13, 20253.1M1.0-48.6%
May 30, 20256.1M8.7+7.4%
May 15, 20255.7M6.0+0.2%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)